13 September 2023
13 September 2023
Mounjaro as a therapy for T2D is likely to gain significant uptake in the primary care space, as well as eventually in specialist weight loss management services.
The latest approval is based on data from the two-part Phase III GENESIS clinical trial.
The company expects the 2023 sales of its CAR-T cell therapy to be up to $570m less than projected and plans to offset this by downsizing.
The biotech received $72m in a Series B extension round from Big Pharma to invest in autoimmune disease research.
Smyraf prevents structural joint damage due to rheumatoid arthritis.
As per the deal terms, shareholders of Axolotl will receive an initial equity price of $65m.
CancerVAX plans to adapt its universal cancer vaccine platform to develop a universal CAR-T cell platform.
LIB will receive milestone payments worth up to $305m on meeting clinical, regulatory and commercial goals in the future.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
